Treatment for Inflammatory Bowel Syndrome

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Milam Hall, Room 001, Corvallis, OR
Inflammatory Bowel Syndrome+2 More
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).

Eligible Conditions

  • Inflammatory Bowel Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Baseline, GMP feeding week 1, 2 and 3 and post study without GMP feeding week 1, 2 and 3

Week 1
Measure the inflammatory markers in stool and blood using immunology multiplex assay
Stool sample based gut microbiome composition using 16S rRNA gene sequencing

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

15 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, gmp feeding week 1, 2 and 3 and post study without gmp feeding week 1, 2 and 3

Trial Background

Prof. Dave Dallas, Assistant Professor
Principal Investigator
Oregon State University
Closest Location: Milam Hall, Room 001 · Corvallis, OR
N/AFirst Recorded Clinical Trial
1 TrialsResearching Inflammatory Bowel Syndrome
0 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are fluent in English.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.